Search Results

You are looking at 1 - 10 of 373 items for :

  • "maintenance" x
Clear All
Full access

Ashraf Z. Badros

Maintenance therapy in multiple myeloma (MM) comprises any therapy given “following completion of induction treatment in responding or nonprogressing patients, with the goal of prolonging survival.” 1 However, maintenance therapy practice

Full access

Chezi Ganzel, Dan Douer and Martin S. Tallman

Maintenance Therapy in Acute Promyelocytic Leukemia The concept of maintenance therapy in acute leukemia has always appealed to investigators contemplating the idea that long-term nonintensive chemotherapy could eradicate residual leukemia

Full access

Keith D. Eaton and Renato G. Martins

/print certificate. Learning Objectives Upon completion of this activity, participants will be able to: Identify medications that have demonstrated efficacy as maintenance chemotherapy for NSCLC Describe clinical trials of maintenance therapy

Full access

Antonio Palumbo and Roberto Mina

cell transplantation (ASCT), and subsequently by the introduction of the immunomodulators thalidomide and lenalidomide, and the proteasome inhibitor bortezomib. 2 Consolidation (2-4 cycles of combination therapies) and maintenance (continuous therapy

Full access

Philip L. McCarthy

continuum for transplant-eligible patients include induction, AHSCT dose-intensive therapy, consolidation, and maintenance. This article focuses on the role of maintenance therapy after AHSCT. An optimal agent for maintaining response should be effective

Full access

Ryan D. Gentzler and Jyoti D. Patel

During the past 10 years, the treatment of advanced-stage non-small cell lung cancer (NSCLC) has become increasingly complex. From the use of newer chemotherapeutics in platinum-based doublets to the introduction of targeted agents and maintenance

Full access

Edmond Marzbani and Elihu Estey

. However the control arm had significantly lower survival, leading some to question the relevance of the study. 7 Maintenance Therapy Maintenance refers to postconsolidation treatment with the goal of improving relapse-free survival. It is generally

Full access

Alessandra Larocca and Antonio Palumbo

therapy with VTD or VRD, and maintenance with TD. The 2-year event-free survival rate was 80%. Although this is a good result, the 2-year PFS with lenalidomide maintenance in CALGB and Institute for Financial Markets (IFM) studies was approximately 75

Full access

Rupali Roy and Leo I. Gordon

maintenance treatment of follicular lymphoma. Follicular Lymphoma Follicular lymphoma is the second most common subtype of lymphoma worldwide and constitutes 22% of all non-Hodgkin's lymphomas (NHL). 5 It is believed to arise from germinal center B

Full access

James M. Cleary, Scott Rodig, Paul M. Barr, Atul B. Shinagare, Jeffrey W. Clark, Geoffrey I. Shapiro and Philippe Armand

writing, it has been 33 months since the patient first started crizotinib. He has been on maintenance crizotinib for 30 months and is experiencing complete remission according to PET/CT. Figure 1 PET/CT scan at (A) baseline and (B) 8 weeks after